1. Academic Validation
  2. Glucocorticoid-remediable aldosteronism

Glucocorticoid-remediable aldosteronism

  • Arq Bras Endocrinol Metabol. 2004 Oct;48(5):682-6. doi: 10.1590/s0004-27302004000500014.
Graham T McMahon 1 Robert G Dluhy
Affiliations

Affiliation

  • 1 Division of Endocrinology, Diabetes & Hypertension, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. gmcmahon@partners.org
Abstract

Glucocorticoid-remediable aldosteronism (GRA) is a monogenic form of human hypertension that predisposes to cerebral hemorrhage. As a result of a chimeric gene duplication, aldosterone is ectopically synthesized in the cortisol-secreting zona fasciculata of the adrenal gland under the control of adrenocorticotropin (ACTH). Hypertension frequently has its onset during childhood and is usually refractory to standard anti-hypertensives such as ACE inhibitors and beta-blockers. Hypokalemia can develop in those treated with a potassium-wasting diuretic, but random potassium levels are usually normal. Diagnosis has been facilitated by the availability of a genetic test. Suppression of ACTH release with exogenous dexamethasone is a useful diagnostic and therapeutic strategy. Treatment with the Mineralocorticoid Receptor antagonists spironolactone and epleronone is also efficacious. The diagnosis of GRA facilitates directed therapies and screening of at-risk individuals and kindreds.

Figures